603658 Autobio Diagnostics
- 46.82
- +0.39+0.84%
Autobio Diagnostics News
Express News | Autobio Diagnostics: Chairman and actual controller Miao Yongjun intends to continue shareholding of 20-40 million yuan.
Autobio Diagnostics (603658.SH) has repurchased 0.4005% of its shares.
On June 3, Gelonhui reported that Autobio Diagnostics (603658.SH) has disclosed that as of May 31, 2024, the company has repurchased a total of 2,347,970 shares through centralized bidding trading, accounting for 0.4005% of the company's total share capital. The highest transaction price was 59.99 yuan/share and the lowest was 51.54 yuan/share. The total amount paid was 129,808,722.60 yuan (excluding transaction fees).
Antu Biotech (603658.SH) plans to pay 1.05 yuan per share in 2023, excluding interest on June 5
Antu Biotech (603658.SH) announced that the company plans to pay a cash dividend of 1.05 yuan per share in 2023,...
Antu Biotech (603658): The 24Q1 profit growth rate exceeded expectations, and the regular business grew steadily
Core view The company's 2023 annual report performance was in line with expectations, and the 24Q1 profit growth rate exceeded expectations. In the second quarter of 2024, despite increased compliance requirements in the medical industry and continued promotion of policies such as DRG/DIP health insurance fee control
Autobio Diagnostics' Unit Gets Nod for Two Products
Chinese medical laboratory technology company Autobio Diagnostics' (SHA:603658) unit, Antu Experimental Instruments (Zhengzhou), received medical device registration certificates from the drug registr
Shareholders in Autobio Diagnostics (SHSE:603658) Are in the Red If They Invested Three Years Ago
Many investors define successful investing as beating the market average over the long term. But the risk of stock picking is that you will likely buy under-performing companies. We regret to report
Antu Biotech: Mining and landing in Anhui will have a positive impact, and the proportion of reagent products will increase | Direct performance
① Mr. Feng Chao, financial director of Antu Biotech, said bluntly during the performance meeting that the share of reagent products will increase in the future; ② Chairman Miao Yongjun predicted the growth rate of the molecular, microbiological and other sectors. Among them, there is little new market space in the biochemical sector; ③ Secretary Fang Ruikuan believes that a national collection meeting is likely, and that the mining and landing in Anhui will have a positive impact on the company.
Express News | Antu Biotech: Wholly-owned subsidiary obtains medical device registration certificate
Express News | Antu Biotech and Gongdong Medical establish medical device companies
Antu Biotech (603658.SH): 0.3250% of shares have been repurchased cumulatively
Gelonghui, May 6, 丨 Antu Biotech (603658.SH) announced that as of April 30, 2024, the company had repurchased 1,905,370 shares through centralized bidding transactions, accounting for 0.3250% of the company's total share capital. The highest transaction price was 59.99 yuan/share, the lowest price was 51.54 yuan/share, and the total amount paid was 105,168,612.90 yuan (not including transaction fees).
Antu Biotech (603658): Rapid overseas growth, profit levels have increased
The company's revenue in 2023 was 4.444 billion yuan (up 0.05% year on year), the company's net profit to mother was 1,217 billion yuan (up 4.28% year on year), and net profit after deducting non-return to mother was 1,185 billion yuan (year over year)
Antu Biotech (603658) Review: Regular business growth is steady, new products are being developed at an accelerated pace
Investment highlights: Event: The company released the 2023 annual report and the first quarter report of 2024. In 2023, the company achieved operating income of 4.444 billion yuan (+0.05%) and net profit to mother of 1,217 billion yuan (
Antu Biotech (603658): Regular business is growing steadily, and profit levels are improving
Matters: The company released financial reports. The company achieved revenue of 4.444 billion yuan (+0.05%) in 23, a year-on-year increase of 16.64% after excluding the impact of COVID-19 testing-related revenue, and net profit of 1,217 billion yuan (+4.2 billion yuan)
Antu Biotech (603658.SH): Chairman and actual controller Miao Yongjun increased the company's shares by 503.68 million yuan
Gelonghui, April 23 | Antu Biotech (603658.SH) announced that on April 23, 2024, Mr. Miao Yongjun, the chairman and actual controller of the company, increased his holdings of the company's shares by 901,200 shares through centralized bidding transactions, accounting for 0.1537% of the company's total share capital. The total amount of this increase in holdings was 503.68 million yuan.
Antu Biotech (603658): The light emitting business will grow steadily in 2023, and profitability will increase steadily
Incident The company published its 2023 annual report and 2024 quarterly report. In 2023, the company achieved operating income of 4.444 billion yuan, a year-on-year increase of 0.05%, and achieved net profit of 1,217 billion yuan to mother, an increase of 4 billion yuan over the previous year
Huaan Securities released a research report on April 22 stating that it gave Antu Biotech (603658.SH) a purchase rating. The main reasons for the rating include: 1) the light emitting business continued to grow steadily, with a growth rate of about 24.88%
Huaan Securities released a research report on April 22 stating that it gave Antu Biotech (603658.SH) a purchase rating. The main reasons for the rating include: 1) the light emitting business continued to grow steadily, with a growth rate of about 24.88% in 2023; 2) R&D investment increased, and gross margin increased as the share of self-produced products increased. (Mainichi Keizai Shimbun)
Antu Biotech (603658): 1Q24 profit grew rapidly year over year, strong dividends increased shareholder returns
The 2023 results are in line with market expectations, and the 1Q24 profit side slightly exceeds market expectations. The company announced 2023 results: revenue of 4.444 billion yuan, which is basically the same as the previous year; net profit to mother of 1,217 billion yuan (YoY+ 4
Antu Biotech (603658): Steady growth of multiple production lines and continuous improvement in profitability
Incident: The company released its 2023 annual report, achieving full year revenue of 4.444 billion yuan (yoy +0.05%), net profit attributable to mother of 1,217 billion yuan (yoy +4.28%), after deducting 11.85 billion yuan of non-return net profit
Earnings Beat: Autobio Diagnostics Co., Ltd. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
The first-quarter results for Autobio Diagnostics Co., Ltd. (SHSE:603658) were released last week, making it a good time to revisit its performance. The results were mixed; although revenues of
Huafu Securities released a research report on April 21 stating that it gave Antu Biotech (603658.SH) a purchase rating, and the target price was 65.48 yuan. The main reasons for the rating include: 1) the company released the 2023 annual report and the 2
Huafu Securities released a research report on April 21 stating that it gave Antu Biotech (603658.SH) a purchase rating, and the target price was 65.48 yuan. The main reasons for the rating include: 1) the company released the 2023 annual report and the 2024 quarterly report, with impressive Q1 profit growth; 2) steady endogenous business growth, improving the business structure to raise profit levels; 3) steady immunological testing revenue and an overall marginal improvement in the gross margin of reagent products; 4) the IVD multi-platform layout is progressing smoothly, and overseas expansion is growing at a high rate, and I am optimistic about the potential for subsequent acceleration. (Mainichi Keizai Shimbun)
Analysis
Price Target
No Data
